Cargando…
Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
BACKGROUND AND AIM: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients. METHODS: We searched PubMed, Web of Scien...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929286/ https://www.ncbi.nlm.nih.gov/pubmed/36816559 http://dx.doi.org/10.3389/fneur.2023.1107474 |
_version_ | 1784888818128650240 |
---|---|
author | Elhalag, Rowan H. Motawea, Karam R. Talat, Nesreen Elsayed Rouzan, Samah S. Shah, Jaffer |
author_facet | Elhalag, Rowan H. Motawea, Karam R. Talat, Nesreen Elsayed Rouzan, Samah S. Shah, Jaffer |
author_sort | Elhalag, Rowan H. |
collection | PubMed |
description | BACKGROUND AND AIM: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients. METHODS: We searched PubMed, Web of Science, Scopus, and Cochrane library databases. We included any randomized control trials and controlled observational studies that investigated the role of vamorolone in treating DMD patients. We used RevMan software, version 5.4. to perform our meta-analysis. RESULTS: After a search of the literature, 4 studies were included in the meta-analysis; the total number of patients included in the study is 277 patients, 125 patients in the vamorolone group, 106 in the glucocorticoids group, and 46 in placebo (steroid naïve) group. The pooled analysis showed a statistically significant association between the vamorolone group and increased TTSTAND velocity, TTRW velocity and TTCLIMB velocity compared with the placebo group (MD = 0.04, 95% CI = 0.02–0.07, p = 0.002), (MD = 0.24, 95% CI = 0.11–0.37, p = 0.0003), and (MD = 0.06, 95% CI = 0.05–0.06, p < 0.00001), respectively. Also, the analysis showed a statistically significant association between vamorolone and increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid group (MD = −0.14, 95% CI = −0.26 to −0.01, p = 0.03) and (MD = 17.82, 95% CI = 3.89–31.75, p = 0.01), respectively. CONCLUSION: Our study revealed a significant association between vamorolone and increased TTSTAND velocity, TTRW velocity, and TTCLIMB velocity compared with the placebo (steroid naïve), also showed a statistically significant association between increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid that enhances the privilege of vamorolone over glucocorticoid in treating DMD patients. More multicenter randomized studies are needed to support our results. |
format | Online Article Text |
id | pubmed-9929286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99292862023-02-16 Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis Elhalag, Rowan H. Motawea, Karam R. Talat, Nesreen Elsayed Rouzan, Samah S. Shah, Jaffer Front Neurol Neurology BACKGROUND AND AIM: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients. METHODS: We searched PubMed, Web of Science, Scopus, and Cochrane library databases. We included any randomized control trials and controlled observational studies that investigated the role of vamorolone in treating DMD patients. We used RevMan software, version 5.4. to perform our meta-analysis. RESULTS: After a search of the literature, 4 studies were included in the meta-analysis; the total number of patients included in the study is 277 patients, 125 patients in the vamorolone group, 106 in the glucocorticoids group, and 46 in placebo (steroid naïve) group. The pooled analysis showed a statistically significant association between the vamorolone group and increased TTSTAND velocity, TTRW velocity and TTCLIMB velocity compared with the placebo group (MD = 0.04, 95% CI = 0.02–0.07, p = 0.002), (MD = 0.24, 95% CI = 0.11–0.37, p = 0.0003), and (MD = 0.06, 95% CI = 0.05–0.06, p < 0.00001), respectively. Also, the analysis showed a statistically significant association between vamorolone and increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid group (MD = −0.14, 95% CI = −0.26 to −0.01, p = 0.03) and (MD = 17.82, 95% CI = 3.89–31.75, p = 0.01), respectively. CONCLUSION: Our study revealed a significant association between vamorolone and increased TTSTAND velocity, TTRW velocity, and TTCLIMB velocity compared with the placebo (steroid naïve), also showed a statistically significant association between increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid that enhances the privilege of vamorolone over glucocorticoid in treating DMD patients. More multicenter randomized studies are needed to support our results. Frontiers Media S.A. 2023-02-01 /pmc/articles/PMC9929286/ /pubmed/36816559 http://dx.doi.org/10.3389/fneur.2023.1107474 Text en Copyright © 2023 Elhalag, Motawea, Talat, Rouzan and Shah. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Elhalag, Rowan H. Motawea, Karam R. Talat, Nesreen Elsayed Rouzan, Samah S. Shah, Jaffer Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis |
title | Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis |
title_full | Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis |
title_fullStr | Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis |
title_full_unstemmed | Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis |
title_short | Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis |
title_sort | efficacy of vamorolone in treatment of duchene muscle dystrophy. a meta-analysis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929286/ https://www.ncbi.nlm.nih.gov/pubmed/36816559 http://dx.doi.org/10.3389/fneur.2023.1107474 |
work_keys_str_mv | AT elhalagrowanh efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis AT motaweakaramr efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis AT talatnesreenelsayed efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis AT rouzansamahs efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis AT shahjaffer efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis |